

QPP#	Measure Title	Code for "Performance Met"	Code for "Denominator Exception"	Code for "Denominator Exclusion"	Code for "Performance Not Met"
249	Barrett's Esophagus Pathology Reporting	<b>3126F</b>  Esophageal biopsy report with a statement about dysplasia (present, absent, or indefinite and if present, contains appropriate grading)	<b>3126F-1P</b>  Documentation of medical reason(s) for not submitting the histological finding of Barrett's mucosa (eg, malignant neoplasm or absence of intestinal metaplasia)  OR  <b>G8797</b>  Not esophageal specimen (Specimen site is other than anatomic location of primary tumor)	None	<b>3126F-8P</b>  Statement about dysplasia (present, absent, or indefinite, and if present, contains appropriate grading) not documented; reason not otherwise specified
250	Radical Prostatectomy Pathology Reporting	<b>3267F</b>  pT Category, pN Category, Gleason Score and Statement about Margin Status Documented	<b>3267F-1P</b>  Documentation of medical reason(s) for not including pT category, pN category, Gleason score and statement about margin status in the pathology report (eg, specimen originated from other malignant neoplasms, transurethral resections of the prostate (TURP), or secondary site prostatic carcinomas)	<b>G8798</b>  Not prostate specimen (Specimen site other than anatomic location of prostate)	<b>3267F-8P</b>  pT, pN, Gleason score and statement about margin status were not documented in pathology report; reason not otherwise specified

NOTE: QPP QDC and CPT II codes have been approved by CMS for claims reporting. CPT only copyright 2026 American Medical Association. All rights reserved.

QPP#	Measure Title	Code for "Performance Met"	Code for "Denominator Exception"	Code for "Denominator Exclusion"	Code for "Performance Not Met"
395	Lung Cancer Reporting (Biopsy/Cytology Specimens)	<b>G9418</b>  Primary non-small cell lung cancer lung biopsy and cytology specimen report documents classification into specific histologic type following IASLC guidance OR classified as NSCLC- NOS with an explanation	<b>G9419</b>  Documentation of medical reason(s) for not including the histological type OR NSCLC- NOS classification with an explanation (e.g. Specimen insufficient or non-diagnostic, specimen does not contain cancer, or other documented medical reasons)	<b>G9420</b>  Not a lung specimen or is not classified as primary non-small cell lung cancer (NSCLC)	<b>G9421</b>  Primary non-small cell lung cancer biopsy and cytology specimen report does not document classification into specific histologic type OR does not follow IASLC guidance; reason not otherwise specified
396	Lung Cancer Reporting (Resection Specimens)	<b>G9422</b>  Primary lung carcinoma resection report documents pT, pN, and for Non-small Cell Lung Cancer, histologic type (Squamous Cell Carcinoma, Adenocarcinoma and NOT NSCLC-NOS)	<b>G9423</b>  Documentation of medical reason(s) for not including pT, pN, and histologic type [For patient with appropriate exclusion criteria (eg, metastatic disease, benign tumors, malignant tumors other than carcinomas, inadequate surgical specimens)]	<b>G9424</b>  Not lung specimen or is classified as non-small cell lung cancer not otherwise specified (NSCLC-NOS)	<b>G9425</b>  Primary lung carcinoma resection report does not document pT, pN, and for non-small cell lung cancer, histologic type (Squamous Cell Carcinoma, Adenocarcinoma) reason not otherwise specified
397	Melanoma Reporting	<b>G9428</b>  Pathology report includes the pT Category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors	<b>G9429</b>  Documentation of medical reason(s) for not including pT Category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors (e.g., negative skin biopsies, insufficient tissue, or other documented medical reasons)	<b>G9430</b>  Not a skin specimen (Specimen site other than anatomic cutaneous location)	<b>G9431</b>  Pathology report does not include the pT Category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors, reason not otherwise specified

NOTE: QPP QDC and CPT II codes have been approved by CMS for claims reporting. CPT only copyright 2023 American Medical Association. All rights reserved.

QPP#	Measure Title	Code for “Performance Met”	Code for “Denominator Exception”	Code for “Denominator Exclusion”	Code for “Performance Not Met”
440*	Skin Cancer: Biopsy Reporting Time – Pathologist to Clinician	<b>G9785</b>  Pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) sent from the Pathologist/ Dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist	<b>M1166</b>  Pathology report for tissue specimens produced from wide local excisions or re-excisions	<b>G9784</b>  Pathologists/Dermatopathologists providing a second opinion on a biopsy  <b>G9939</b>  Pathologists/Dermatopathologists is the same clinician who performed the biopsy	<b>G9786</b>  Pathology report diagnosing cutaneous basal cell carcinoma, squamous cell carcinoma, or melanoma (to include in situ disease) was not sent from the Pathologist/ Dermatopathologist to the biopsying clinician for review within 7 days from the time when the tissue specimen was received by the pathologist
491*	Mismatch Repair (MMR) or Microsatellite Instability (MSI) Biomarker Testing Status in Colorectal Carcinoma, Endometrial, Gastroesophageal, or Small Bowel Carcinoma	<b>M1193</b>  Surgical pathology reports that contain impression or conclusion of or recommendation for testing of MMR by immunohistochemistry, MSI by DNA-based testing status, or both	<b>M1194</b>  Documentation of medical reason(s) surgical pathology reports did not contain impression or conclusion of or recommendation for testing of MMR by immunohistochemistry, MSI by DNA-based testing status, or both tests were not included (e.g., patient will not be treated with checkpoint inhibitor therapy, no residual carcinoma is present in the sample [tissue exhausted or status post neoadjuvant treatment], insufficient tumor for testing)	<b>M1467</b> Patients with an existing diagnosis of Lynch Syndrome  <b>M1192</b> Patients with an existing diagnosis of squamous cell carcinoma of the esophagus  <b>M1191</b> Hospice services provided to patient any time during the measurement period:	<b>M1195</b>  Surgical pathology reports that do not contain impression or conclusion of or recommendation for testing of MMR by immunohistochemistry, MSI by DNA-based testing status, or both, reason not given

\* QPP 440 and QPP 491 are Registry-only measures. These measures CANNOT be reported through Claims

NOTE: CPT only copyright 2023 American Medical Association. All rights reserved.